Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Don't Floss, You Lose - (ATRX) To the RESCUE. -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (175)	4/16/2002 1:24:43 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 182

Tuesday April 16, 1:20 pm Eastern Time Press Release SOURCE: Atrix Laboratories, Inc. Atrix Submits New Drug Application to FDA for Eligard(TM) 30 mg Depot Prostate Cancer Product Company Reports Positive Phase III Results for Eligard 30 mg Four-Month Depot FORT COLLINS, Colo., April 16 /PRNewswire-FirstCall/ -- Atrix Laboratories, Inc. (Nasdaq: ATRX - news) announced today that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Eligard(TM) 30 mg four-month leuprolide acetate depot product, for the treatment of advanced prostate cancer. This is the third NDA the Company has submitted in 13 months. ``The submission of a third NDA in just over one year is testimony to our focus on achievement,'' said David R. Bethune, Atrix's chairman and chief executive officer. ``The addition of the Eligard 30 mg to our one-month and three-month products will allow us to participate in the entire market of $1.2 billion.''